Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | G6PD | P11413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17237810 | 1.00 | TSHR (0.37) | TSHRALDH1A1PEPDPOLBLMNA | |
| SCHEMBL17237802 | 0.88 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL17237804 | 0.88 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL10518657 | 0.82 | — | — | |
| SCHEMBL30258997 | 0.80 | — | — | |
| SCHEMBL22834824 | 0.80 | — | — | |
| SCHEMBL22259326 | 0.80 | — | — | |
| SCHEMBL22234675 | 0.80 | — | — | |
| SCHEMBL17254600 | 0.80 | — | — | |
| SCHEMBL30259026 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604536-B2 | Substituted cyclopropanes as PDE-10 inhibitors | Sunovion Pharamaceuticals Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-2861596-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180258104-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharamaceuticals Inc. | 2018-09-13 | — | — | US | disclosed |
| US-9994590-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170037060-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2017-02-09 | — | — | US | disclosed |
| US-9505751-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150322090-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322090-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | TSHR 1653/4885ALDH1A1 560/4885PEPD 1362/4885 |
| US-20170037060-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | TSHR 1653/4885ALDH1A1 560/4885PEPD 1362/4885 |
| US-20180258104-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | TSHR 1653/4885ALDH1A1 560/4885PEPD 1362/4885 |
| US-10604536-B2 | Substituted cyclopropanes as PDE-10 inhibitors | PDE10A, PDE2A, PDE3A | TSHR 2664/4885ALDH1A1 818/4885PEPD 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.